CN102940669B - 一种治疗心脑血管病的药物组合物 - Google Patents
一种治疗心脑血管病的药物组合物 Download PDFInfo
- Publication number
- CN102940669B CN102940669B CN201210428250.6A CN201210428250A CN102940669B CN 102940669 B CN102940669 B CN 102940669B CN 201210428250 A CN201210428250 A CN 201210428250A CN 102940669 B CN102940669 B CN 102940669B
- Authority
- CN
- China
- Prior art keywords
- extract
- caulis sargentodoxae
- pharmaceutical composition
- radix notoginseng
- cerebrovascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 29
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 23
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 39
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 28
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 28
- 239000000284 extract Substances 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000009636 Huang Qi Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 238000010992 reflux Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000545442 Radix Species 0.000 claims description 7
- 241001061264 Astragalus Species 0.000 claims description 6
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 claims description 6
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 6
- 244000131316 Panax pseudoginseng Species 0.000 claims description 6
- 235000006533 astragalus Nutrition 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 3
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 239000009910 sargent gloryvine Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 28
- 238000012360 testing method Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 206010008118 cerebral infarction Diseases 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 210000001715 carotid artery Anatomy 0.000 description 6
- 210000001168 carotid artery common Anatomy 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 239000012891 Ringer solution Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 4
- 230000006793 arrhythmia Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920002955 Art silk Polymers 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020919 Hypervolaemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000531807 Psophiidae Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- -1 transfusion Substances 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210428250.6A CN102940669B (zh) | 2012-10-31 | 2012-10-31 | 一种治疗心脑血管病的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210428250.6A CN102940669B (zh) | 2012-10-31 | 2012-10-31 | 一种治疗心脑血管病的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102940669A CN102940669A (zh) | 2013-02-27 |
CN102940669B true CN102940669B (zh) | 2014-05-14 |
Family
ID=47723729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210428250.6A Active CN102940669B (zh) | 2012-10-31 | 2012-10-31 | 一种治疗心脑血管病的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102940669B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110882323B (zh) * | 2019-06-17 | 2022-04-29 | 广西中医药大学附属瑞康医院 | 一种增强亚健康人体质的颗粒剂及其制备方法 |
CN115043814B (zh) * | 2022-06-30 | 2023-02-24 | 黑龙江中医药大学 | 一种用于治疗心肌缺血的药物及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101433584A (zh) * | 2008-12-12 | 2009-05-20 | 上海禾丰制药有限公司 | 治疗气虚血瘀型冠心病的药物组合物及其制备方法 |
CN101829183A (zh) * | 2010-05-18 | 2010-09-15 | 上海市浦东新区人民医院 | 一种以抗血小板体积异常原理防治心脑血管病的中药制剂 |
CN101732402B (zh) * | 2010-01-27 | 2012-06-06 | 浙江中医药大学 | 一种防治缺血性脑损伤的药物及其制备方法 |
CN101897752B (zh) * | 2009-05-31 | 2013-05-22 | 金士力佳友(天津)有限公司 | 一种中药组合物及其制备方法 |
-
2012
- 2012-10-31 CN CN201210428250.6A patent/CN102940669B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101433584A (zh) * | 2008-12-12 | 2009-05-20 | 上海禾丰制药有限公司 | 治疗气虚血瘀型冠心病的药物组合物及其制备方法 |
CN101897752B (zh) * | 2009-05-31 | 2013-05-22 | 金士力佳友(天津)有限公司 | 一种中药组合物及其制备方法 |
CN101732402B (zh) * | 2010-01-27 | 2012-06-06 | 浙江中医药大学 | 一种防治缺血性脑损伤的药物及其制备方法 |
CN101829183A (zh) * | 2010-05-18 | 2010-09-15 | 上海市浦东新区人民医院 | 一种以抗血小板体积异常原理防治心脑血管病的中药制剂 |
Non-Patent Citations (2)
Title |
---|
倪士峰等.大血藤化学成分及药学研究进展.《中国野生植物资源》.2004,(第04期), |
大血藤化学成分及药学研究进展;倪士峰等;《中国野生植物资源》;20040825(第04期);第9页 * |
Also Published As
Publication number | Publication date |
---|---|
CN102940669A (zh) | 2013-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102847063A (zh) | 一种治疗气血两虚血瘀型糖尿病足的中药组合物及其制备方法 | |
CN101244234B (zh) | 防治缺血和出血性脑血管疾病的药物及其制备方法 | |
CN100447148C (zh) | 栀子提取物在制备治疗心脑血管病的药物中的应用 | |
CN102940669B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN101987112B (zh) | 一种治疗心脑血管病的药物组合物及其制备方法 | |
CN102961517B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN102940668B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN102940680B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN102940675B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN104147032A (zh) | 一种用于防治缺血性中风相关疾病的药物组合物及其制备方法和用途 | |
CN104055909A (zh) | 复方阿胶浆在制备经期保健的药物中的应用 | |
CN102940658A (zh) | 一种治疗心脑血管病的药物组合物 | |
CN102940676B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN102940657A (zh) | 一种治疗心脑血管病的药物组合物 | |
CN102940694B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN104367630A (zh) | 一种含有西洋参的治疗心脑血管疾病的药物组合物 | |
CN104367656A (zh) | 一种含有山楂叶的治疗心脑血管疾病的药物组合物 | |
CN102940702B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN104435213A (zh) | 一种含有柿子叶的治疗心脑血管病的中药组合物 | |
CN100415241C (zh) | 一种治疗心脑血管病的药物组合物 | |
CN104435664A (zh) | 一种含有赤小豆的治疗心脑血管疾病的药物组合物 | |
CN100381125C (zh) | 一种治疗心脑血管病的药物组合物 | |
CN104398550A (zh) | 一种含有银杏叶的治疗心脑血管病的中药组合物 | |
CN104435106A (zh) | 一种含有丹参的治疗心脑血管疾病的药物组合物 | |
CN104435107A (zh) | 一种含有川芎的治疗心脑血管疾病的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NANTONG YUEYUE INDUSTRY CO., LTD. Free format text: FORMER OWNER: CHENGDU YILUKANG MEDICAL TECHNOLOGY SERVICE CO., LTD. Effective date: 20150317 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 226131 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150317 Address after: 226131 Jiangsu city of Nantong Province Haimen Yuelai town Fuxing Road, building 12, the town government compound Patentee after: Nantong Yue Yue Industrial Co., Ltd. Address before: Science Park high tech Zone of Chengdu South Road, No. 88 610041 Sichuan province Tianfu Life Science Park building B6 No. 9 Patentee before: Chengdu Yilukang Medical Technology & Service Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191111 Address after: 363200, Zhangzhou, Fujian province Zhangpu Sui An Industrial Zone Patentee after: Tongyitang Pharmaceutical Co., Ltd. Address before: 226131, Jiangsu, Nantong Haimen town, Fuxing Road, building 12, the town government compound Patentee before: Nantong Yue Yue Industrial Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20220513 Address after: 343000 No. 283, Jingjiu Avenue, Jinggangshan economic and Technological Development Zone, Ji'an City, Jiangxi Province Patentee after: JIANGXI KANGZHIKANG APPARATUS CO.,LTD. Address before: 363200 Suian Industrial Zone, Zhangpu County, Zhangzhou City, Fujian Province Patentee before: TONGYITANG PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |